Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression.

ABSTRACT: The glutamatergic modulator ketamine has been shown to rapidly reduce depressive symptoms in patients with treatment-resistant major depressive disorder (TRD). Although its mechanisms of action are not fully understood, changes in cortical excitation/inhibition (E/I) following ketamine administration are well documented in animal models and could represent a potential biomarker of treatment response. Here, we analyse neuromagnetic virtual electrode time series collected from the primary somatosensory cortex in 18 unmedicated patients with TRD and in an equal number of age-matched healthy controls during a somatosensory 'airpuff' stimulation task. These two groups were scanned as part of a clinical trial of ketamine efficacy under three conditions: (a) baseline; (b) 6-9 h following subanest

SUBMITTER: Fagerholm ED 

PROVIDER: S-EPMC8164631 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature